Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Nat Cancer. 2023 Sep;4(9):1345-1361. doi: 10.1038/s43018-023-00630-y. Epub 2023 Sep 21.
Nat Cancer. 2023.
PMID: 37743366
Free PMC article.
Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants.
[No authors listed]
[No authors listed]
Nat Cancer. 2023 Sep;4(9):1220-1221. doi: 10.1038/s43018-023-00631-x.
Nat Cancer. 2023.
PMID: 37743367
No abstract available.
Item in Clipboard
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I, Odintsov I, Ishida K, Lui AJW, Kato M, Suzuki T, Zhang T, Wakayama K, Kurth RI, Cheng R, Fujita H, Delasos L, Vojnic M, Khodos I, Yamada Y, Ishizawa K, Mattar MS, Funabashi K, Chang Q, Ohkubo S, Yano W, Terada R, Giuliano C, Lu YC, Bonifacio A, Kunte S, Davare MA, Cheng EH, de Stanchina E, Lovati E, Iwasawa Y, Ladanyi M, Somwar R.
Miyazaki I, et al.
Nat Cancer. 2023 Oct;4(10):1526. doi: 10.1038/s43018-023-00663-3.
Nat Cancer. 2023.
PMID: 37814012
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite